Understand ALS treatment options: A Clinical Overview of Medicines, Supportive Care, and Research

Understanding ALS treatment options requires separating therapies intended to modify disease progression from supportive measures designed to preserve function, communication, nutrition, breathing, comfort, and independence. ALS is a progressive motor neuron disease involving nerve cells in the brain and spinal cord, and treatment is individualized because symptoms and progression vary substantially between people. 1

Disease-modifying medicines

Riluzole is an approved ALS medicine that is thought to reduce harmful glutamate signaling. It is available in oral tablet and liquid forms, and regulatory information describes it as a treatment that may prolong survival rather than reverse established motor-neuron damage. Treatment decisions generally consider diagnosis, overall health, swallowing ability, liver monitoring requirements, potential adverse effects, and the patient’s goals. 5

Edaravone, marketed in oral and intravenous formulations, is an antioxidant treatment approved to slow decline in physical functioning for some people with ALS. Its suitability depends on clinical factors, administration considerations, and local regulatory availability. Neither riluzole nor edaravone is a cure, and clinical benefit is generally described as limited or modest, making continued neurological assessment important. 63

Genetic eligibility and regulatory changes

Tofersen is a gene-targeted antisense oligonucleotide for adults with ALS associated with a confirmed pathogenic or likely pathogenic SOD1 mutation. SOD1-related disease represents approximately 2% of ALS cases, so genetic testing can be relevant when clinical history, family history, or specialist assessment raises that possibility. Eligibility is not established by symptoms alone and requires appropriate genetic evaluation and interpretation. 74

Relyvrio, also known as AMX0035, illustrates why regulatory status and trial evidence must be reviewed separately from earlier announcements. The treatment received accelerated approval, but its manufacturer later announced voluntary withdrawal after a Phase 3 study failed to demonstrate clinical benefit. Availability and prescribing rules can change, so treatment information should be checked against current guidance from qualified clinicians and regulators. 8

Breathing and respiratory care

Respiratory weakness is a central concern in ALS because the diaphragm and other breathing muscles can gradually lose strength. Non-invasive ventilation, commonly delivered through a mask with equipment such as BiPAP, can support breathing when respiratory function declines. Respiratory assessments may therefore become a recurring part of care, with decisions based on symptoms, testing, tolerance, sleep-related breathing problems, and personal preferences. 9

Respiratory management also involves discussing airway clearance, secretion handling, cough effectiveness, sleep quality, and future care preferences. The timing and type of intervention differ among individuals, and equipment may require fitting, maintenance, cleaning, monitoring, and adjustment. These practical demands can affect comfort and adherence. A respiratory specialist working within an ALS team can help interpret changing measurements and coordinate equipment needs. 19

Mobility, rehabilitation, and daily function

Physical therapy focuses on maintaining mobility, managing pain, supporting safe movement, and maximizing functional independence without causing excessive fatigue. Occupational therapy addresses changing physical capabilities and may help adapt activities, assistive techniques, and home environments. Because weakness can progress, equipment and routines often need periodic reassessment rather than a single permanent adjustment. 1011

• Physical therapy may address movement, positioning, contracture prevention, and safe activity.
• Occupational therapy may address personal care, household tasks, seating, transfers, and environmental adaptations.
• Assistive devices can change as limb weakness, balance problems, or fatigue develop.

Rehabilitation planning must balance activity with energy conservation and safety. ALS affects motor function, while sensation is often preserved, but stiffness, cramps, weakness, and fatigue can complicate movement. A coordinated plan can also address falls, pressure areas, posture, and caregiver demands. The goal is not to restore damaged motor neurons, but to support participation and reduce avoidable complications. 110

Speech, swallowing, and nutrition

Speech-language therapy is used when ALS causes dysarthria, voice changes, chewing difficulty, or swallowing problems. Communication support may include strategy training and assistive communication devices, particularly when speech becomes less reliable. Swallowing assessment helps identify aspiration concerns and guides food texture, eating strategies, positioning, and decisions about how to maintain adequate hydration and nutrition. 12

Weight loss, prolonged meals, choking, or aspiration risk can lead clinicians to discuss enteral nutrition through a percutaneous endoscopic gastrostomy, commonly called a PEG tube. Tube placement is a medical decision influenced by nutritional status, respiratory condition, swallowing safety, and personal preferences. It may supplement oral intake or become the primary route for nutrition, but it does not halt ALS progression. 13

Multidisciplinary care and emerging research

Multidisciplinary ALS clinics commonly coordinate neurologists, respiratory specialists, dietitians, physical and occupational therapists, speech-language professionals, nurses, and psychosocial support. This model helps connect disease-modifying treatment with symptom control, equipment planning, nutrition, breathing support, communication, and advance-care discussions. The care plan changes as weakness spreads from one body region to another or as respiratory and swallowing needs evolve. 144

Research includes gene therapies, stem-cell approaches, biomarker-guided strategies, and additional pharmacological targets, but these approaches should not be treated as established cures. A 2026 review characterized currently available disease-modifying therapies as offering limited efficacy and noted that emerging biological treatments remain an active research area. Clinical trials may involve strict eligibility criteria, uncertain benefit, monitoring burdens, and potential risks, so participation requires specialist discussion and informed consent. 3

What treatment planning involves

ALS treatment planning typically begins with confirming the diagnosis and documenting the pattern and pace of functional change. Diagnosis may involve electromyography, nerve-conduction studies, magnetic resonance imaging, laboratory testing, and exclusion of other disorders. Once ALS is established, clinicians consider disease-modifying medicines, genetic testing, breathing status, swallowing, nutrition, mobility, communication, cognition, caregiver capacity, and the person’s priorities. 1

There is no single treatment schedule that applies to every patient. Some people experience limb-predominant weakness, while others first develop speech or swallowing problems, and cognitive effects can occur in a subset of individuals. Treatment benefits are measured against side effects, administration demands, equipment maintenance, travel requirements, cost and insurance issues, and changing goals. Prognosis and decisions about future interventions should be discussed directly with the treating ALS team. 24

Sources

1. Merck Manual Professional Edition, Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases
2. Yale Medicine, Amyotrophic Lateral Sclerosis
3. Frontiers in Neurology, Current and Emerging Therapeutic Strategies for ALS
4. ALS News Today, Disease-Modifying Therapies and Symptom Management
5. U.S. Food and Drug Administration, Information on Rilutek and Riluzole
6. Mayo Clinic, Amyotrophic Lateral Sclerosis Diagnosis and Treatment
7. National Institute of Neurological Disorders and Stroke, Amyotrophic Lateral Sclerosis
8. ALS Association, Announcement Regarding Withdrawal of Relyvrio
9. Johns Hopkins Medicine, ALS Treatment
10. Cleveland Clinic, Amyotrophic Lateral Sclerosis
11. WebMD, ALS Treatment and Care
12. ALS Therapy Development Institute, ALS Treatment
13. MedlinePlus Genetics, Amyotrophic Lateral Sclerosis
14. Neurology Advisor, Multidisciplinary Care in ALS